An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
QIAGEN Launches CE-marked Version of QuantiFERON® SARS-CoV-2 to Assess T-cell Response to COVID-19
Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
covid-19
Rhea-AI Summary
QIAGEN has announced the CE marking of its QuantiFERON® SARS-CoV-2 assay, which measures T-cell responses to SARS-CoV-2, enhancing the assessment of immunity post-COVID-19 vaccination. Unlike traditional serology tests, this assay evaluates both CD4+ and CD8+ T-cell responses, providing deeper insights into immune responses. The technology is designed for ease of use, requiring only whole blood and no lymphocyte purification. T-cell responses offer critical information on the immune system's effectiveness against COVID-19 over time.
Positive
CE marking received for QuantiFERON® SARS-CoV-2 assay, indicating regulatory approval.
Technology recognized for ease of use, improving accessibility for healthcare providers.
Negative
None.
Easy-to-use workflow can detect T-cell response early in the course of COVID-19 infection or following vaccination
Detection of T-cells can provide vital insights that completes the picture of SARS-CoV-2 immune response – beyond serology alone
Cell-mediated immunity can also be assessed in individuals who have been vaccinated
HILDEN, Germany & GERMANTOWN, Md.--(BUSINESS WIRE)--
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today the CE marking of its QuantiFERON® SARS-CoV-2 assay that measures T-cell responses to SARS-CoV-2 and aids in the assessment of immunity in individuals who have received COVID-19 vaccination.
COVID-19 vaccines stimulate the body to produce antibodies and activate T-cells to fight a SARS-CoV-2 infection. Serology tests, which measure the antibodies, often generate positive test results after vaccination but are unable to assess cellular responses. The QuantiFERON® SARS-CoV-2 assay detects CD4+ and CD8+ T-cell responses, thereby enabling a much more comprehensive assessment of immunity generated by COVID-19 vaccines.
The QuantiFERON® SARS-CoV-2 assay is based on QIAGEN’s QuantiFERON® interferon gamma release technology, which is globally recognized as an easy-to-use T-cell assay that employs whole blood and – unlike other T-cell assays – does not require the purification of lymphocytes for T-cell measurement.
“T-cells provide valuable insights into our immune system’s response to COVID-19,” said Jean-Pascal Viola, Senior Vice President and Head of the Molecular Diagnostics Business Area at QIAGEN. “The more we know about this epidemic, the better equipped the world will be to address this threat that will stay with us,” he said. “We are excited about our QuantiFERON technology enabling the assessment of immune responses that are crucial for the prevention and management of the disease.”
T-cell response to SARS-CoV-2 declines much more slowly than antibody response and may indicate how severe the course of an illness triggered by SARS-CoV-2 will be in infected patients, and how immune those are who have recovered many months – possibly even years – after having been infected.
Further information on the product can be found at here.
About QIAGEN
QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective workflows. QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare), Applied Testing (primarily forensics), Pharma (pharma and biotech companies) and Academia (life sciences research). As of September 30, 2021, QIAGEN employed approximately 6,000 people in over 35 locations worldwide. Further information can be found at http://www.qiagen.com.
Forward-Looking Statement
Certain statements contained in this press release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein relating to QIAGEN's products, collaborations markets, strategy or operating results, including without limitation its expected adjusted net sales and adjusted diluted earnings results, are forward-looking, such statements are based on current expectations and assumptions that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations, regulatory processes and dependence on logistics), variability of operating results and allocations between customer classes, the commercial development of markets for our products to customers in academia, pharma, applied testing and molecular diagnostics; changing relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN's products (including fluctuations due to general economic conditions, the level and timing of customers' funding, budgets and other factors); our ability to obtain regulatory approval of our products; difficulties in successfully adapting QIAGEN's products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitors' products; market acceptance of QIAGEN's new products and the integration of acquired technologies and businesses. For further information, please refer to the discussions in reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission (SEC).
Public Relations
Thomas Theuringer, +49 2103 29 11826
e-mail: pr@QIAGEN.com
Source: QIAGEN N.V.
FAQ
What is the QuantiFERON® SARS-CoV-2 assay by QIAGEN?
The QuantiFERON® SARS-CoV-2 assay is a test that detects T-cell responses to SARS-CoV-2, providing insights into immune responses after COVID-19 vaccination.
When did QIAGEN receive CE marking for its T-cell assay?
QIAGEN announced the CE marking for its QuantiFERON® SARS-CoV-2 assay on December 1, 2021.
How does the QuantiFERON® assay differ from traditional serology tests?
Unlike serology tests that detect antibodies, the QuantiFERON® assay measures both CD4+ and CD8+ T-cell responses, allowing for a more comprehensive assessment of immunity.
What is the significance of T-cell responses in COVID-19 immunity?
T-cell responses can indicate the strength and duration of immunity against SARS-CoV-2, offering insights into potential disease severity and recovery.
What company ticker symbol should I look for QIAGEN?
The ticker symbol for QIAGEN on the New York Stock Exchange is QGEN.
